Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences (Nasdaq: CSTL), a healthcare company specializing in innovative diagnostic tests, has announced its upcoming participation in two major investor conferences in March 2025. The company's executive management will present at the Leerink Partners Global Healthcare Conference on March 10 at 1:40 p.m. Eastern time, and the KeyBanc Capital Markets Healthcare Forum (virtual) on March 18 at 11:15 a.m. Eastern time.
Both presentations will be accessible via live audio webcasts through Castle Biosciences' investor relations website, with replay options available after the events conclude.
Castle Biosciences (Nasdaq: CSTL), una società sanitaria specializzata in test diagnostici innovativi, ha annunciato la sua prossima partecipazione a due importanti conferenze per investitori a marzo 2025. La direzione esecutiva dell'azienda presenterà alla Leerink Partners Global Healthcare Conference il 10 marzo alle 13:40 ora orientale, e al KeyBanc Capital Markets Healthcare Forum (virtuale) il 18 marzo alle 11:15 ora orientale.
Entrambe le presentazioni saranno accessibili tramite webcast audio dal vivo attraverso il sito web delle relazioni con gli investitori di Castle Biosciences, con opzioni di replay disponibili dopo la conclusione degli eventi.
Castle Biosciences (Nasdaq: CSTL), una empresa de atención médica especializada en pruebas diagnósticas innovadoras, ha anunciado su próxima participación en dos importantes conferencias para inversores en marzo de 2025. La dirección ejecutiva de la compañía presentará en la Leerink Partners Global Healthcare Conference el 10 de marzo a la 1:40 p.m. hora del Este, y en el KeyBanc Capital Markets Healthcare Forum (virtual) el 18 de marzo a las 11:15 a.m. hora del Este.
Ambas presentaciones serán accesibles a través de transmisiones en vivo de audio a través del sitio web de relaciones con inversores de Castle Biosciences, con opciones de repetición disponibles después de que concluyan los eventos.
캐슬 바이오사이언스 (Nasdaq: CSTL)는 혁신적인 진단 테스트를 전문으로 하는 헬스케어 회사로, 2025년 3월에 두 개의 주요 투자자 회의에 참여할 예정이라고 발표했습니다. 회사의 경영진은 3월 10일 동부 표준시 오후 1시 40분에 리어링크 파트너스 글로벌 헬스케어 컨퍼런스에서 발표하며, 3월 18일 동부 표준시 오전 11시 15분에 키뱅크 캐피탈 마켓 헬스케어 포럼 (온라인)에서 발표할 예정입니다.
두 발표 모두 캐슬 바이오사이언스의 투자자 관계 웹사이트를 통해 실시간 오디오 웹캐스트로 접근할 수 있으며, 이벤트가 종료된 후 다시 보기 옵션도 제공됩니다.
Castle Biosciences (Nasdaq: CSTL), une entreprise de santé spécialisée dans les tests diagnostiques innovants, a annoncé sa prochaine participation à deux grandes conférences pour investisseurs en mars 2025. La direction exécutive de l'entreprise présentera à la Leerink Partners Global Healthcare Conference le 10 mars à 13h40, heure de l'Est, et au KeyBanc Capital Markets Healthcare Forum (virtuel) le 18 mars à 11h15, heure de l'Est.
Les deux présentations seront accessibles via des webcasts audio en direct sur le site web des relations avec les investisseurs de Castle Biosciences, avec des options de rediffusion disponibles après la fin des événements.
Castle Biosciences (Nasdaq: CSTL), ein Gesundheitsunternehmen, das sich auf innovative diagnostische Tests spezialisiert hat, hat seine bevorstehende Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 bekannt gegeben. Das Management des Unternehmens wird am 10. März um 13:40 Uhr Eastern Time auf der Leerink Partners Global Healthcare Conference präsentieren und am 18. März um 11:15 Uhr Eastern Time auf dem KeyBanc Capital Markets Healthcare Forum (virtuell).
Beide Präsentationen werden über Live-Audio-Webcasts auf der Investor-Relations-Website von Castle Biosciences zugänglich sein, mit Wiederholungsoptionen, die nach dem Ende der Veranstaltungen verfügbar sind.
- None.
- None.
- Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40 p.m. Eastern time.
- KeyBanc Capital Markets Healthcare Forum, occurring virtually on March 18, 2025, at 11:15 a.m. Eastern time.
Live audio webcasts of the Company’s presentations will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. Replays of the webcasts will be available following the conclusion of the broadcasts.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225883000/en/
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
When is Castle Biosciences (CSTL) presenting at the Leerink Partners Conference in 2025?
How can investors access Castle Biosciences' (CSTL) March 2025 conference presentations?
Which investor conferences will Castle Biosciences (CSTL) attend in March 2025?
What time is Castle Biosciences' (CSTL) virtual presentation at the KeyBanc Healthcare Forum?
